Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.trsl.2019.07.007 http://scihub22266oqcxt.onion/10.1016/j.trsl.2019.07.007 31476281!6848786!31476281     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=31476281&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Transl+Res 2019 ; 214 (?): 17-29 Nephropedia Template TP {{tp|p=31476281|t=2019. siRNA- and miRNA-based therapeutics for liver fibrosis |pdf=|usr=}}{{31476281}} gab.com Text siRNA- and miRNA-based therapeutics for liver fibrosis JO: Transl Res http://www.kidney.de/pget.php?&tw=1&pmid=31476281 #FOAvip Liver fibrosis is a wound-healing process induced by chronic liver injuries, such as nonalcoholic steatohepatitis, hepatitis, alcohol abuse, and metal poisoning. The accumulation of excessive extracellular matrix (ECM) in the liver is a key characteristic of liver fibrosis. Activated hepatic stellate cells (HSCs) are the major producers of ECM and therefore play irreplaceably important roles during the progression of liver fibrosis. Liver fibrogenesis is highly correlated with the activation of HSCs, which is regulated by numerous profibrotic cytokines. Using RNA interference to downregulate these cytokines in activated HSCs is a promising strategy to reverse liver fibrosis. Meanwhile, microRNAs (miRNAs) have also been exploited for the treatment of liver fibrosis. This review focuses on the current siRNA- and miRNA-based liver fibrosis treatment strategies by targeting activated HSCs in the liver. Twit Text FOAVip siRNA- and miRNA-based therapeutics for liver fibrosis ????Transl Res http://www.kidney.de/pget.php?&tw=1&pmid=31476281 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=31476281 #FOAvip English Wikipedia <ref>{{Cite pmid|31476281}}</ref> siRNA- and miRNA-based therapeutics for liver fibrosis #MMPMID31476281 Zhao Z; Lin CY; Cheng K Transl Res 2019[Dec]; 214 (?): 17-29 PMID31476281show ga Liver fibrosis is a wound-healing process induced by chronic liver injuries, such as nonalcoholic steatohepatitis, hepatitis, alcohol abuse, and metal poisoning. The accumulation of excessive extracellular matrix (ECM) in the liver is a key characteristic of liver fibrosis. Activated hepatic stellate cells (HSCs) are the major producers of ECM and therefore play irreplaceably important roles during the progression of liver fibrosis. Liver fibrogenesis is highly correlated with the activation of HSCs, which is regulated by numerous profibrotic cytokines. Using RNA interference to downregulate these cytokines in activated HSCs is a promising strategy to reverse liver fibrosis. Meanwhile, microRNAs (miRNAs) have also been exploited for the treatment of liver fibrosis. This review focuses on the current siRNA- and miRNA-based liver fibrosis treatment strategies by targeting activated HSCs in the liver. |Animals[MESH] |Humans[MESH] |Liver Cirrhosis/genetics/*therapy[MESH] |MicroRNAs/*therapeutic use[MESH] |Models, Biological[MESH] |RNA, Small Interfering/*therapeutic use[MESH]siRNA- and miRNA-based therapeutics for liver fibrosis (epmc).pdf DeepDyve Pubget Overpricing